NICE, the health technology appraisal institute for England and Wales, has given a final thumbs up to Napp Pharmaceuitcals's Levact (bendamustine) for some patients with chronic lymphocytic leukaemia (CLL).

NICE, the health technology appraisal institute for England and Wales, has today recommended Napp's chemotherapy drug Levact (bendamustine) for treating patients with chronic lymphocytic leukaemia. The institute was so impressed with the strength of the evidence supporting the product that it jumped Levact straight to the final stages of guidance development.

Rachel Cummings has been appointed health policy and advocacy manager in the UK corporate affairs department at Napp Pharmaceuticals. She joins from Racepoint Group, where she was associate director.